		Accèss DB#
	SEARCH REQUEST FORM	24500 me
	Scientific and Technical Information Cente	712
Requester's Full Name Mike Art Unit: 165 Phone	Examiner #: 694 Number 308-4230 Serial Number:	104 pate: 9/6/00
Mail Box and Bldg/Room Location	on://De Poor Results Format Preferred	(circle) PAPER DISK E-MAIL
**********	mitted, please prioritize searches in order	********
Include the elected species or structures.	te search topic, and describe as specifically as possible, keywords, synonyms, acronyms, and registry number is that may have a special meaning. Give examples or r sheet, pertinent claims, and abstract.	s, and combine with the concept or
Title of Invention: Hyper	icin & Hypericum	extract.
Inventors (please provide full names):	Jacque like J. Shan,	Xi-den Wu,
Earliest Priority Filing Date:	7/9/99	
For Sequence Searches Only Please incl appropriate serial number.	lude all pertinent information (parent, child, divisional, or	issued patent numbers) along with the
flease seaves	L compound cla	ims 2,45-
18-21	<i>I</i>	
y,		1
		L
T 2801 EN US		
RECE SEP - CIVON (S)		Point of Contact
		Susan Hanley Inical Info, Specialist
A	CM1	12C14 Tel: 305-4053
X 8		
* For	Cucan Ham	lov X
- (*1) 1UV	on an in	
STAFF USE ONLY Searcher Hanley	Type of Search Vendors and NA Sequence (#) STN	cost where applicable
2 State of the sta		

Searcher Location: Structure (#) Questel/Orbit Date Searcher Picked Up Bibliographic Dr.Link Date Completed: Litigation Lexis/Nexis Fulltext Searcher Prep & Review Time: Sequence Systems Patent Family WWW/Internet Clerical Prep Time: 120 mm Other Other (specify) Online Time:

PTO-1590 (1-2000)

What is claimed is:

1. A method of treating a health disorder treatable with a T-type calcium channel blocker in an animal in need of such a treatment, comprising administering an effective amount of an active agent to said animal, wherein said active agent is *Hypericum perforatum*, a *Hypericum extract*, an extract of a species of the *Hypericum* genus other than *Hypericum perforatum*, a *Hypericum* constituent, a hypericin derivative or a hypericin analog, with the proviso that when the active agent is *Hypericum perforatum* or *Hypericum* extract, said health disorder is not depression or migraine headache.

The method of claim 1, wherein said hypericin derivative is a compound of formula II.

15

20

25

10

wherein

R₁ is H, OH, OR or OCOR;

R₂ is H, R, F, Cl, Br, I or SO₃H;

 $\rm R_3$ is H, R, OH, OR, OCOR, $\rm CH_2OH$, $\rm CH_2OR$, $\rm CH_2OCOR$, COOH or COOR;

 $\rm R_4$ is H, R, OH, OR, OCOR, $\rm CH_2OH, \, CH_2OR, \, CH_2OCOR, \, COOH$ or COOR;

R₅ is H, R, F, Cl, Br, I or SO₃H;

R₆ is H, OH, OR or OCOR;

R₇ is H, OH, OR or OCOR;

R₈ is H, R, F, Cl, Br, I or SO₃H;

 R_9 is H, R, OH, OR, OCOR, CH_2OH , CH_2OR , CH_2OCOR , COOH or 30 COOR;

R₁₀ is H, R, OH, OR, OCOR, CH₂OH, CH₂OR, CH₂OCOR, COOH or COOR;

R₁₁ is H, R, F, Cl, Br, I or SO₂H:

R₁₂ is H, OH, OR or OCOR; and

R is an optionally substituted C_1 - C_{30} alkyl group; with the proviso that the following compounds are excluded

- (A) a compound of formula II, wherein R_1 , R_3 , R_4 , R_6 , R_7 and R_{12} are OH, R_2 , R_5 , R_8 and R_{11} are H, and R_9 and R_{10} are methyl;
- (B) a compound of formula II, wherein R_1 , R_9 , R_{10} , R_6 , R_7 and R_{12} are OH, R_2 , R_5 , R_8 and R_{11} are H, and R_3 and R_4 are methyl;
- (C) a compound of formula II, wherein R_1 , R_3 , R_4 , R_6 , R_7 and R_{12} are OH, R_2 , R_5 , R_8 and R_{11} are H, R_9 is methyl, and R_{10} is CH_2OH ;
- (D) a compound of formula II, wherein R_1 , R_3 , R_4 , R_6 , R_7 and R_{12} are OH, R₂, R₅, R₈ and R₁₁ are H, R₉ is CH₂OH and R₁₀ is methyl;
- (E) a compound of formula II, wherein R_1 , R_9 , R_{10} , R_6 , R_7 and R_{12} are OH, $\rm R_2,\,R_5,\,R_8$ and $\rm R_{11}$ are H, $\rm R_3$ is methyl, and $\rm R_4$ is $\rm CH_2OH;$ and
- (F) a compound of formula II, wherein R_1 , R_9 , R_{10} , R_6 , R_7 and R_{12} are OH, R_2 , R_5 , R_8 and R_{11} are H, R_3 is CH_2OH and R_4 is methyl.
- 3. The method of claim 1, wherein the health disorder treatable with T-type calcium channel blockers is depression, chronic heart failure, congestive heart failure, ischaemc condition, arrhythmia, angina pectoris, hyperinsulinemia, diabete > mellitus, hypertension, hypoinsulinemia, hyperaldosteronemia, epilepsy, (migraine headache) brain aging? a Fridadedi 1, lah neurodegenerative disease or preterm labor.
- The method of claim 1, wherein said Hypericum constituent is hypericin, pseudohypericin, hyperforin, ashyperforin, quercetin, quercitrin, isoquercitrin, hyperoside, rutin, amentoflavone or hyperin.
- 25 The method of claim 2, wherein R is a C_1 - C_{30} alkyl group, optionally substituted with one to three substituents independently selected from hydroxy, alkoxy, acyloxy, carboxy, akoxycarbonyl, amino, alkylamino, dialkylamino, nitro or phenyl group or fluorine, chlorine, bromine or iodine atom.

30 The method of claim 5, wherein R, is H, OH, OR or OCOR; R₂ is H or R;

R₃ is H, OH, OR, OCOR, CH₂OH, CH₂OR or CH₂OCOR;

5

10

15

20

15

20

R₄ is H, OH, OR, OCOR, CH₂OH, CH₂OR or CH₂OCOR;

R₅ is H or R;

R₆ is H, OH, OR or OCOR;

R₇ is H, OH, OR or OCOR;

5 R_8 is H or R;

R₉ is H, OH, OR, OCOR, CH₂OH, CH₂OR or CH₂OCOR;

R₁₀ is H, OH, OR, OCOR, CH₂OH, CH₂OR or CH₂OCOR;

R₁₁ is H or R;

R₁₂ is H, OH, OR or OCOR; and

10 R is an optionally substituted C₁-C₆ alkyl group.

7. The method of claim 6, wherein R is an optionally substituted methyl or ethyl group.

- 8. The method of claim 1, wherein said animal is a human.
- 9. The method of claim 1, wherein said active agent is a *Hypericum* extract.
- 10. The method of claim 9, wherein said effective amount is about 0.05 mg to 500 mg per kg body weight of said animal.
 - 11. The method of claim 1, wherein said active agent is hypericin.
- 12. The method of claim 11, wherein said effective amount is about 0.0015 mg to 15 mg per kg body weight of said animal.
- 13. The method of claim 1, <u>further comprising</u> administering to said animal an additional active agent as described in claim 1.
- 14. The method of claim 13, wherein one of the active agents administered is hypericin.
- 25 15. The method of claim 14, wherein another of the active agents administered is pseudohypericin.
 - 16. The method of claim 14, wherein another of the <u>active agents</u> administered is <u>hyperforin</u>.
- 17. The method of claim 15, further comprising administering 30 hyperforin to said animal.

A compound of formula II,

11

wherein

R, is H, OH, OR or OCOR;

R₂ is H, R, F, Cl, Br, I or SO₃H;

10 R₃ is H, R, OH, OR, OCOR, CH₂OH, CH₂OR, CH₂OCOR, COOH or COOR;

R₄ is H, R, OH, OR, OCOR, CH₂OH, CH₂OR, CH₂OCOR, COOH or COOR;

R₅ is H, R, F, Cl, Br, I or SO₃H;

R is H, OH, OR or OCOR;

R₇ is H, OH, OR or OCOR;

R₈ is H, R, F, Cl, Br, I or SO₃H;

R₉ is H, R, OH, OR, OCOR, CH₂OH, CH₂OR, CH₂OCOR, COOH or COOR;

20 R₁₀ is H, R, OH, OR, OCOR, CH₂OH, CH₂OR, CH₂OCOR, COOH or COOR;

R₁₁ is H, R, F, Cl, Br, I or SO₃H;

Riz is H, OH, OR or OCOR; and

R is an optionally substituted C₁-C₃₀ alkyl group;

25 with the proviso that the following compounds are excluded

 $VZ_6(A)$ a compound of formula II, wherein R_1 , R_3 , R_4 , R_6 , R_7 and R_{12} are OH, R_2 , R_5 , R_8 and R_{11} are H, and R_9 and R_{10} are methyl;

L27 (B) a compound of formula II, wherein R₁, R₉, R₁₀, R₆, R₇ and R₁₂ are OH, R₂, R₅, R₈ and R₁₁ are H, and R₃ and R₄ are methyl;

30 $\downarrow \chi \$ (C) a compound of formula II, wherein R₁, R₃, R₄, R₆, R₇ and R₁₂ are OH, R₂, R₅, R₈ and R₁₁ are H, R₉ is methyl, and R₁₀ is CH₂OH;

(D) a compound of formula II, wherein R_1 , R_3 , R_4 , R_6 , R_7 and R_{12} are OH, R_2 , R_5 , R_8 and R_{11} are H, R_9 is CH₂OH and R_{10} is methyl;

15

 $\[\] \[\] \$

 V_{0} (F) a compound of formula II, wherein R₁, R₉, R₁₀, R₆, R₇ and R₁₂ are OH, R₂, R₅, R₈ and R₁₁ are H, R₃ is CH₂OH and R₄ is methyl.

19. The compound of claim 18, wherein R is a C_1 - C_{30} alkyl group, optionally substituted with one to three substituents independently selected from hydroxy, alkoxy, acyloxy, carboxy, akoxycarbonyl, amino, alkylamino, dialkylamino, nitro or phenyl group or fluorine, chlorine, bromine or iodine atom.

10

5

20. The compound of claim 18, wherein 6

R₂ is H or R;

R₃ is H, OH, OR, OCOR, CH₂OH, CH₂OR or CH₂OCOR;

R₄ is H, OH, OR, OCOR, CH₂OH, CH₂OR or CH₂OCOR;

15 R_s is H or R;

R₆ is H, OH, OR or OCOR;

R₇ is H, OH, OR or OCOR;

R₈ is H or R;

R₉ is H, OH, OR, OCOR, CH₂OH, CH₂OR or CH₂OCOR;

R₁₀ is H, OH, OR, OCOR, CH₂OH, CH₂OR or CH₂OCOR;

R₁₁ is H or R;

R₁₂ is H, OH, OR or OCOR; and

R is an optionally substituted C₁-C₆ alkyl group.

- 21. The compound of claim 20, wherein R is an optionally substituted methyl or ethyl group.
- 22. The method of claim 1, wherein said extract of a species of the Hypericum genus other than Hypericum perforatum is an extract of a species selected from the group consisting of H. majus, H. formosum, H. calycinum, H. X møseranum, H. irazuense, H. reductum, H. patulum, H. mutilum, H. cruxandreae, H. hypericoides, H. densiflorum, H. prolificum, H. frondosum, H. cumilicola, H. anagalloides, H. androsaemum, H. tetrapterum, H. hirsutum, H. olympicum, H. hyssopifølium, H. elongatum and H. erratum.

30

20